BPI-1178 drug page Clinical trials

Trials with BPI-1178

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

1Trials
0Recruiting
1Countries
224Planned patients

Showing 1–1 of 1

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
Finished Phase 1 224 patients NCT04282031

BPI-1178 is a novel, orally administered inhibitor of both cyclin-dependent kinase 4(CDK4)and CDK6 kinase activity. This Phase I study is a first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, and pharmacoki…

China Jun 2020 – Jun 2025 Interventional
Combined with: FulvestrantLetrozole